Format

Send to

Choose Destination
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:333-352. doi: 10.1146/annurev-pharmtox-010919-023537. Epub 2019 Jul 23.

Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data.

Author information

1
Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.
2
Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.
3
Departments of Obstetrics and Gynecology, and Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA; email: d.aronoff@vumc.org.

Abstract

The promise of drug repurposing is to accelerate the translation of knowledge to treatment of human disease, bypassing common challenges associated with drug development to be more time- and cost-efficient. Repurposing has an increased chance of success due to the previous validation of drug safety and allows for the incorporation of omics. Hypothesis-generating omics processes inform drug repurposing decision-making methods on drug efficacy and toxicity. This review summarizes drug repurposing strategies and methodologies in the context of the following omics fields: genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics, phenomics, pregomics, and personomics. While each omics field has specific strengths and limitations, incorporating omics into the drug repurposing landscape is integral to its success.

KEYWORDS:

big data; drug development; drug repurposing; omics; precision medicine

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center